$6-7 million NPAT in FY18

What a wonderful presentation.

So many impressive take aways from today's update although the 3 most important for me were,

-On going partnership discussions involving our vaccine division and our CardioCel division.

-An almost obsessive like focus on return on investment. This business is really going to be run, for the first time, like a business with profit as it's major objective and focus.

-A net profit after tax of $6-7 million in FY18 (the financial year ending June 30th 2018) growing to $11-12 million in FY19 and $19 million in FY20.

Businesses commanding this type of performance will often attract P/E ratios of 50+ so if they can execute on these plans then investors look set to realise massive capital gains over the following years.

Great job Wayne, thank you for your efforts, we're lucky to have you at the helm and I hope you'll remain there.